Cargando…

Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells

Anlotinib, a multitarget tyrosine kinase inhibitor, is effective as a third-line treatment against non-small cell lung cancer (NSCLC). However, acquired resistance occurs during its administration. To understand the molecular mechanisms of anlotinib resistance, we characterized chromatin accessibili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Le-le, Lu, Jun, Liu, Rui-qi, Hu, Min-juan, Zhao, Yi-ming, Tan, Sheng, Wang, Shu-yuan, Zhang, Bo, Nie, Wei, Dong, Yu, Zhong, Hua, Zhang, Wei, Zhao, Xiao-dong, Han, Bao-hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608858/ https://www.ncbi.nlm.nih.gov/pubmed/32415222 http://dx.doi.org/10.1038/s41401-020-0421-7

Ejemplares similares

TFAP2 paralogs facilitate chromatin access for MITF at pigmentation and cell proliferation genes
por: Kenny, Colin, et al.
Publicado: (2022)

Correction: TFAP2 paralogs facilitate chromatin access for MITF at pigmentation and cell proliferation genes
Publicado: (2022)

Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C
por: Fang, Fuxiao, et al.
Publicado: (2022)

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021)

Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
por: Yang, Qian, et al.
Publicado: (2020)

Distinct Activities of Tfap2A and Tfap2B in the Specification of GABAergic Interneurons in the Developing Cerebellum
por: Zainolabidin, Norliyana, et al.
Publicado: (2017)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
por: Wang, Zhi‐Ming, et al.
Publicado: (2020)

TFAP2A Induced KRT16 as an Oncogene in Lung Adenocarcinoma via EMT
por: Yuanhua, Liu, et al.
Publicado: (2019)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Control of directionality of chromatin folding for the inter- and intra-domain contacts at the Tfap2c–Bmp7 locus
por: Tsujimura, Taro, et al.
Publicado: (2018)

Functional Divergence of Mammalian TFAP2a and TFAP2b Transcription Factors for Bidirectional Sleep Control
por: Hu, Yang, et al.
Publicado: (2020)

Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer
por: Lu, Jun, et al.
Publicado: (2019)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
por: Zhang, Xiaohua, et al.
Publicado: (2020)

Antitumor effects of anlotinib in thyroid cancer
por: Ruan, Xianhui, et al.
Publicado: (2018)

TFAP2A Induced ITPKA Serves as an Oncogene and Interacts with DBN1 in Lung Adenocarcinoma
por: Guoren, Zhou, et al.
Publicado: (2020)

Identification of functional TFAP2A and SP1 binding sites in new TFAP2A-modulated genes
por: Orso, Francesca, et al.
Publicado: (2010)

TFAP2B mutation and dental anomalies
por: Tanasubsinn, Natchaya, et al.
Publicado: (2017)

Computational modeling of chromatin accessibility identified important epigenomic regulators
por: Zhao, Yanding, et al.
Publicado: (2022)

MicroRNA-124 suppresses the invasion and proliferation of breast cancer cells by targeting TFAP4
por: Cha, Nier, et al.
Publicado: (2021)

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells
por: Lu, Jun, et al.
Publicado: (2019)

Case report of severe pneumothorax due to lung cancer treated with anlotinib
por: Lu, Haowei, et al.
Publicado: (2023)

Successful treatment of advanced ovarian cancer with anlotinib: a case report
por: Zhang, Ping, et al.
Publicado: (2020)

Anlotinib enhances the antitumor immunity of radiotherapy by activating cGAS/STING in non-small cell lung cancer
por: Han, Dong, et al.
Publicado: (2022)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
por: Ren, Biyong, et al.
Publicado: (2021)

TFAP2A potentiates lung adenocarcinoma metastasis by a novel miR-16 family/TFAP2A/PSG9/TGF-β signaling pathway
por: Xiong, Yanlu, et al.
Publicado: (2021)

TfAP-2 is required for night sleep in Drosophila
por: Kucherenko, Mariya M., et al.
Publicado: (2016)

Correction: Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells
por: Lu, Jun, et al.
Publicado: (2022)

Determination of Anlotinib, a Tyrosine Kinase Inhibitor, in Rat Plasma by UHPLC-MS/MS and Its Application to a Pharmacokinetic Study
por: Wang, Zhe, et al.
Publicado: (2019)

Malignant solitary fibrous tumor in the central nervous system treated with surgery, radiotherapy and anlotinib: A case report
por: Zhang, Dong-Yong, et al.
Publicado: (2022)

Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study
por: Chu, Tianqing, et al.
Publicado: (2022)

Overexpression of Tfap2a in Mouse Oocytes Impaired Spindle and Chromosome Organization
por: Lin, Juan, et al.
Publicado: (2022)

The Landscape of Accessible Chromatin during Yak Adipocyte Differentiation
por: Zhang, Zhilong, et al.
Publicado: (2022)

Characterization of Chromatin Accessibility in Fetal Bovine Chondrocytes
por: Zhang, Qi, et al.
Publicado: (2023)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Fragile Gene WWOX Guides TFAP2A/TFAP2C-Dependent Actions Against Tumor Progression in Grade II Bladder Cancer
por: Kołat, Damian, et al.
Publicado: (2021)

A Serum Metabolomic Study Reveals Changes in Metabolites During the Treatment of Lung Cancer-Bearing Mice with Anlotinib
por: Pan, Xiaoting, et al.
Publicado: (2021)

Overexpression of transcription factor activating enhancer binding protein 4 (TFAP4) predicts poor prognosis for colorectal cancer patients
por: Wei, Jianchang, et al.
Publicado: (2017)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature
por: Zhang, Yu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_29oslvd6gha4a966f8e3qasnhb